These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 33884259)

  • 21. Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population.
    Lee SW; Yang SS; Lien HC; Peng YC; Ko CW; Lee TY
    J Clin Med; 2022 Mar; 11(5):. PubMed ID: 35268535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies.
    Sun W; Cabrera R
    J Gastrointest Cancer; 2018 Jun; 49(2):107-115. PubMed ID: 29453759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy.
    Sekiguchi S; Tsuchiya K; Yasui Y; Inada K; Kirino S; Yamashita K; Hayakawa Y; Osawa L; Higuchi M; Takaura K; Maeyashiki C; Kaneko S; Tamaki N; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Okamoto R; Kurosaki M; Izumi N
    Cancer Rep (Hoboken); 2022 Nov; 5(11):e1613. PubMed ID: 35302279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib.
    Rimini M; Kudo M; Tada T; Shigeo S; Kang W; Suda G; Jefremow A; Burgio V; Iavarone M; Tortora R; Marra F; Lonardi S; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Kumada T; Iwamoto H; Aoki T; Goh MJ; Sakamoto N; Siebler J; Hiraoka A; Niizeki T; Ueshima K; Sho T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Tani J; Nakamura S; Nouso K; Tsutsui A; Nagano T; Takaaki T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y; Cucchetti A; Ratti F; Aldrighetti L; Cascinu S; Casadei-Gardini A
    ESMO Open; 2021 Dec; 6(6):100330. PubMed ID: 34847382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field.
    Doycheva I; Thuluvath PJ
    J Clin Exp Hepatol; 2019; 9(5):588-596. PubMed ID: 31695249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequencing Systemic Therapy in Hepatocellular Carcinoma.
    Ponvilawan B; Roth MT
    Curr Treat Options Oncol; 2023 Nov; 24(11):1580-1597. PubMed ID: 37843628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib following Immunotherapy: A Real World Evidence Study.
    Palmer ME; Gile JJ; Storandt MH; Jin Z; Zemla TJ; Tran NH; Mahipal A
    Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
    Gordan JD; Kennedy EB; Abou-Alfa GK; Beal E; Finn RS; Gade TP; Goff L; Gupta S; Guy J; Hoang HT; Iyer R; Jaiyesimi I; Jhawer M; Karippot A; Kaseb AO; Kelley RK; Kortmansky J; Leaf A; Remak WM; Sohal DPS; Taddei TH; Wilson Woods A; Yarchoan M; Rose MG
    J Clin Oncol; 2024 May; 42(15):1830-1850. PubMed ID: 38502889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic therapy for hepatocellular carcinoma: current status and future perspectives.
    Furuse J; Ueno M; Ikeda M
    Jpn J Clin Oncol; 2021 Aug; 51(9):1363-1371. PubMed ID: 34258616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic Therapy in Metastatic Hepatocellular Carcinoma.
    Elms D; Badami A; Dhanarajan A
    Curr Gastroenterol Rep; 2022 May; 24(5):65-71. PubMed ID: 35416635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted agents for second-line treatment of advanced hepatocellular carcinoma.
    Personeni N; Pressiani T; Bozzarelli S; Rimassa L
    World J Gastrointest Oncol; 2019 Oct; 11(10):788-803. PubMed ID: 31662820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
    Peng W; Pan Y; Xie L; Yang Z; Ye Z; Chen J; Wang J; Hu D; Xu L; Zhou Z; Chen M; Fang A; Zhang Y
    Therap Adv Gastroenterol; 2024; 17():17562848241237631. PubMed ID: 38645513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC.
    Lee J; Sung PS; Yang H; Lee SK; Nam HC; Yoo SH; Lee HL; Kim HY; Lee SW; Kwon JH; Jang JW; Kim CW; Nam SW; Bae SH; Choi JY; Yoon SK
    J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33371271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review.
    Falette Puisieux M; Pellat A; Assaf A; Ginestet C; Brezault C; Dhooge M; Soyer P; Coriat R
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study.
    Yoo C; Kim JH; Ryu MH; Park SR; Lee D; Kim KM; Shim JH; Lim YS; Lee HC; Lee J; Tai D; Chan SL; Ryoo BY
    Liver Cancer; 2021 Apr; 10(2):107-114. PubMed ID: 33977087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenvatinib mesylate to treat hepatocellular carcinoma.
    Ielasi L; Tovoli F; Piscaglia F
    Drugs Today (Barc); 2019 May; 55(5):305-313. PubMed ID: 31131841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
    Bangaru S; Marrero JA; Singal AG
    Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy.
    Burgio V; Iavarone M; Di Costanzo GG; Marra F; Lonardi S; Tamburini E; Piscaglia F; Masi G; Celsa C; Foschi FG; Silletta M; Amoruso DC; Rimini M; Bruccoleri M; Tortora R; Campani C; Soldà C; Viola MG; Forgione A; Conti F; Salani F; Catanese S; Giacchetto CM; Fulgenzi C; Coppola C; Lampertico P; Pellino A; Rancatore G; Cabibbo G; Ratti F; Pedica F; Della Corte A; Colombo M; De Cobelli F; Aldrighetti L; Cascinu S; Casadei-Gardini A
    Cancer Manag Res; 2021; 13():9379-9389. PubMed ID: 34992463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma.
    Terashima T; Yamashita T; Takata N; Toyama T; Shimakami T; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
    Hepatol Res; 2020 Jul; 50(7):871-884. PubMed ID: 32307874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib.
    Chen YY; Wang CC; Liu YW; Li WF; Chen YH
    PeerJ; 2020; 8():e10382. PubMed ID: 33240675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.